|
|
| | CP-105,696 Basic information |
| Product Name: | CP-105,696 | | Synonyms: | CP-105,696;1-[(3S,4R)-4-hydroxy-3-[(4-phenylphenyl)methyl]-3,4-dihydro-2H-chromen-7-yl]cyclopentane-1-carboxylic acid;1-((3S,4R)-3-([1,1'-biphenyl]-4-ylmethyl)-4-hydroxychroman-7-yl)cyclopentane-1-carboxylic acid;CP 105696; CP105696; CP-105696; UNII-Z7354TW4BM; PFIZER 105696;Pfizer 105696;UNII-Z7354TW4BM;Cyclopentanecarboxylic acid, 1-[(3S,4R)-3-([1,1'-biphenyl]-4-ylmethyl)-3,4-dihydro-4-hydroxy-2H-1-benzopyran-7-yl]-;CP-105,696 >=98% (HPLC) | | CAS: | 158081-99-3 | | MF: | C28H28O4 | | MW: | 428.52 | | EINECS: | | | Product Categories: | API | | Mol File: | 158081-99-3.mol |  |
| | CP-105,696 Chemical Properties |
| Boiling point | 651.2±55.0 °C(Predicted) | | density | 1.252±0.06 g/cm3(Predicted) | | storage temp. | room temp | | solubility | Soluble in DMSO | | pka | 4.35±0.20(Predicted) | | form | powder | | color | white to beige |
| | CP-105,696 Usage And Synthesis |
| Uses | CP-105,696 has been used as a leukotriene B4 receptor (LTB4R) antagonist to study the influence of the LTB4 pathway in the pathogenesis of acute itch flares in irritant calcipotriol (MC903)+ model allergen ovalbumin (OVA) sensitized murine model of atopic dermatitis (AD)-like disease. | | Biochem/physiol Actions | CP-105,696 is an orally active, potent and selective leukotriene B4 receptor (LTB4R) antagonist (IC50 against [3H]LTB4 = 5.6 nM for binding human neutrophils; IC50 = 9.7 nM & 30.3 nM, respectively using guinea pig spleen or mouse membranes) that targets LTB4R high- and low-affinity binding sites in a LTB4 non-competitive and competitive manner, respectively. CP-105,696 inhibits 5 nM LTB4-induced human neutrophils chemotaxis and CDllb upregualtion (IC50 = 5.2 nM and 430 nM, respectively) without inhibiting cyclooxygenase activity or affecting chemotaxis induced by C5a, PAF, IL-8. Oral administration is efficacious against intradermal LTB4 (100 ng/mouse), but not IL-1, injection-induced neutrophil accumulation in mice and guinea pigs (ED50 = 4.2 and 0.26 mgkg, respectively). CP-105,696 in vivo efficacy is also demonstrated in other animal models, including collagen-induced arthritis (CIA; 0.3-10 mg/kg in mice), allergic encephalomyelitis (ED50= 8.6 mg/kg; mice), and asthma (10-30 mg/kg; primate). |
| | CP-105,696 Preparation Products And Raw materials |
|